Mineralys Therapeutics, Common Stock Current Valuation
| MLYS Stock | 16.87 0.14 0.84% |
Valuation analysis of Mineralys Therapeutics, helps investors to measure Mineralys Therapeutics,'s intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value is likely to gain to about 710.1 M in 2025, whereas Enterprise Value Over EBITDA is likely to drop (2.64) in 2025. Fundamental drivers impacting Mineralys Therapeutics,'s valuation include:
Overvalued
Today
Please note that Mineralys Therapeutics,'s price fluctuation is slightly risky at this time. Calculation of the real value of Mineralys Therapeutics, is based on 3 months time horizon. Increasing Mineralys Therapeutics,'s time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Mineralys stock is determined by what a typical buyer is willing to pay for full or partial control of Mineralys Therapeutics, Common. Since Mineralys Therapeutics, is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Mineralys Stock. However, Mineralys Therapeutics,'s intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 16.87 | Real 14.84 | Target 32.57 | Hype 16.87 | Naive 18.94 |
The intrinsic value of Mineralys Therapeutics,'s stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Mineralys Therapeutics,'s stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Mineralys Therapeutics, Common helps investors to forecast how Mineralys stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Mineralys Therapeutics, more accurately as focusing exclusively on Mineralys Therapeutics,'s fundamentals will not take into account other important factors: Mineralys Therapeutics, Common Company Current Valuation Analysis
Mineralys Therapeutics,'s Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Mineralys Therapeutics, Current Valuation | 861.23 M |
Most of Mineralys Therapeutics,'s fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mineralys Therapeutics, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Mineralys Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Mineralys Therapeutics, is extremely important. It helps to project a fair market value of Mineralys Stock properly, considering its historical fundamentals such as Current Valuation. Since Mineralys Therapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Mineralys Therapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Mineralys Therapeutics,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Mineralys Current Valuation Historical Pattern
Today, most investors in Mineralys Therapeutics, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Mineralys Therapeutics,'s growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Mineralys Therapeutics, current valuation as a starting point in their analysis.
Mineralys Therapeutics, Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Mineralys Therapeutics, Common has a Current Valuation of 861.23 M. This is 94.0% lower than that of the Biotechnology sector and 81.46% lower than that of the Health Care industry. The current valuation for all United States stocks is 94.82% higher than that of the company.
Mineralys Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mineralys Therapeutics,'s direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mineralys Therapeutics, could also be used in its relative valuation, which is a method of valuing Mineralys Therapeutics, by comparing valuation metrics of similar companies.Mineralys Therapeutics, is currently under evaluation in current valuation category among its peers.
Mineralys Therapeutics, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Mineralys Therapeutics,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Mineralys Therapeutics,'s managers, analysts, and investors.Environmental | Governance | Social |
Mineralys Fundamentals
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | 861.23 M | ||||
| Shares Outstanding | 62.8 M | ||||
| Shares Owned By Insiders | 2.00 % | ||||
| Shares Owned By Institutions | 87.07 % | ||||
| Number Of Shares Shorted | 1.75 M | ||||
| Price To Book | 5.54 X | ||||
| EBITDA | (192.4 M) | ||||
| Net Income | (177.81 M) | ||||
| Total Debt | 14.65 M | ||||
| Book Value Per Share | 3.84 X | ||||
| Cash Flow From Operations | (166.31 M) | ||||
| Short Ratio | 5.94 X | ||||
| Earnings Per Share | (3.66) X | ||||
| Target Price | 38.29 | ||||
| Number Of Employees | 51 | ||||
| Beta | 1.51 | ||||
| Market Capitalization | 1.06 B | ||||
| Total Asset | 205.9 M | ||||
| Retained Earnings | (302.52 M) | ||||
| Working Capital | 190.71 M | ||||
| Net Asset | 205.9 M |
About Mineralys Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mineralys Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mineralys Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mineralys Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.